Fluoxetine 40-60 mg versus fluoxetine 20 mg in the treatment of children and adolescents with a less-than-complete response to nine-week treatment with fluoxetine 10-20 mg

A pilot study

John H. Heiligenstein, Sharon L. Hoog, Karen Wagner, Robert L. Findling, Nora Galil, Stuart Kaplan, Joan Busner, Mary E. Nilsson, Eileen B. Brown, Jennie G. Jacobson

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Objective: The aim of this study was to compare fluoxetine dosage titration to 40-60 mg/day with fixed fluoxetine 20-mg/day treatment for an additional 10 weeks in pediatric outpatients with major depressive disorder (MDD) who had not met protocol-defined response criteria after 9-week acute fluoxetine treatment. Methods: Patients unresponsive (less than or equal to 30% decrease in Children's Depression Rating Scale-Revised [CDRS-R] score) after 9-week fluoxetine treatment were randomly reassigned to continue at 20 mg/day or to increase to 40 mg/day. After 4 weeks, patients unresponsive to 40 mg/day could receive 60 mg/day. Results: Twenty-nine (29) patients, 9-17 years of age, received fluoxetine 40-60 mg/day (n = 14) or 20 mg/day (n = 15). At the conclusion of this study phase, 10 patients (71%) on 40-60 mg/day met the response criteria, versus 5 patients (36%) on 20 mg/day (p = 0.128). Mean CDRS-R scores improved in both treatment groups (fluoxetine 40-60 mg/day, -9.4; fluoxetine 20 mg/day, -1.5; p = 0.099). Adverse events were similar in both groups. However, this study phase was statistically underpowered for detecting differences between treatment groups. Conclusion: More than two thirds of patients whose dosage was increased responded within 10 weeks, suggesting dose escalation may benefit some patients. Approximately one third of patients unresponsive to initial treatment with fluoxetine 20 mg responded to this fixed dosage within another 10 weeks. Fluoxetine 20-60 mg/day was well tolerated.

Original languageEnglish (US)
Pages (from-to)207-217
Number of pages11
JournalJournal of Child and Adolescent Psychopharmacology
Volume16
Issue number1-2
DOIs
StatePublished - Feb 2006

Fingerprint

Fluoxetine
Therapeutics
Depression
Major Depressive Disorder
Outpatients
Pediatrics

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Psychiatry and Mental health
  • Pediatrics, Perinatology, and Child Health
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Fluoxetine 40-60 mg versus fluoxetine 20 mg in the treatment of children and adolescents with a less-than-complete response to nine-week treatment with fluoxetine 10-20 mg : A pilot study. / Heiligenstein, John H.; Hoog, Sharon L.; Wagner, Karen; Findling, Robert L.; Galil, Nora; Kaplan, Stuart; Busner, Joan; Nilsson, Mary E.; Brown, Eileen B.; Jacobson, Jennie G.

In: Journal of Child and Adolescent Psychopharmacology, Vol. 16, No. 1-2, 02.2006, p. 207-217.

Research output: Contribution to journalArticle

Heiligenstein, John H. ; Hoog, Sharon L. ; Wagner, Karen ; Findling, Robert L. ; Galil, Nora ; Kaplan, Stuart ; Busner, Joan ; Nilsson, Mary E. ; Brown, Eileen B. ; Jacobson, Jennie G. / Fluoxetine 40-60 mg versus fluoxetine 20 mg in the treatment of children and adolescents with a less-than-complete response to nine-week treatment with fluoxetine 10-20 mg : A pilot study. In: Journal of Child and Adolescent Psychopharmacology. 2006 ; Vol. 16, No. 1-2. pp. 207-217.
@article{c0e0a7389a0849d0b0bac3e3812197ca,
title = "Fluoxetine 40-60 mg versus fluoxetine 20 mg in the treatment of children and adolescents with a less-than-complete response to nine-week treatment with fluoxetine 10-20 mg: A pilot study",
abstract = "Objective: The aim of this study was to compare fluoxetine dosage titration to 40-60 mg/day with fixed fluoxetine 20-mg/day treatment for an additional 10 weeks in pediatric outpatients with major depressive disorder (MDD) who had not met protocol-defined response criteria after 9-week acute fluoxetine treatment. Methods: Patients unresponsive (less than or equal to 30{\%} decrease in Children's Depression Rating Scale-Revised [CDRS-R] score) after 9-week fluoxetine treatment were randomly reassigned to continue at 20 mg/day or to increase to 40 mg/day. After 4 weeks, patients unresponsive to 40 mg/day could receive 60 mg/day. Results: Twenty-nine (29) patients, 9-17 years of age, received fluoxetine 40-60 mg/day (n = 14) or 20 mg/day (n = 15). At the conclusion of this study phase, 10 patients (71{\%}) on 40-60 mg/day met the response criteria, versus 5 patients (36{\%}) on 20 mg/day (p = 0.128). Mean CDRS-R scores improved in both treatment groups (fluoxetine 40-60 mg/day, -9.4; fluoxetine 20 mg/day, -1.5; p = 0.099). Adverse events were similar in both groups. However, this study phase was statistically underpowered for detecting differences between treatment groups. Conclusion: More than two thirds of patients whose dosage was increased responded within 10 weeks, suggesting dose escalation may benefit some patients. Approximately one third of patients unresponsive to initial treatment with fluoxetine 20 mg responded to this fixed dosage within another 10 weeks. Fluoxetine 20-60 mg/day was well tolerated.",
author = "Heiligenstein, {John H.} and Hoog, {Sharon L.} and Karen Wagner and Findling, {Robert L.} and Nora Galil and Stuart Kaplan and Joan Busner and Nilsson, {Mary E.} and Brown, {Eileen B.} and Jacobson, {Jennie G.}",
year = "2006",
month = "2",
doi = "10.1089/cap.2006.16.207",
language = "English (US)",
volume = "16",
pages = "207--217",
journal = "Journal of Child and Adolescent Psychopharmacology",
issn = "1044-5463",
publisher = "Mary Ann Liebert Inc.",
number = "1-2",

}

TY - JOUR

T1 - Fluoxetine 40-60 mg versus fluoxetine 20 mg in the treatment of children and adolescents with a less-than-complete response to nine-week treatment with fluoxetine 10-20 mg

T2 - A pilot study

AU - Heiligenstein, John H.

AU - Hoog, Sharon L.

AU - Wagner, Karen

AU - Findling, Robert L.

AU - Galil, Nora

AU - Kaplan, Stuart

AU - Busner, Joan

AU - Nilsson, Mary E.

AU - Brown, Eileen B.

AU - Jacobson, Jennie G.

PY - 2006/2

Y1 - 2006/2

N2 - Objective: The aim of this study was to compare fluoxetine dosage titration to 40-60 mg/day with fixed fluoxetine 20-mg/day treatment for an additional 10 weeks in pediatric outpatients with major depressive disorder (MDD) who had not met protocol-defined response criteria after 9-week acute fluoxetine treatment. Methods: Patients unresponsive (less than or equal to 30% decrease in Children's Depression Rating Scale-Revised [CDRS-R] score) after 9-week fluoxetine treatment were randomly reassigned to continue at 20 mg/day or to increase to 40 mg/day. After 4 weeks, patients unresponsive to 40 mg/day could receive 60 mg/day. Results: Twenty-nine (29) patients, 9-17 years of age, received fluoxetine 40-60 mg/day (n = 14) or 20 mg/day (n = 15). At the conclusion of this study phase, 10 patients (71%) on 40-60 mg/day met the response criteria, versus 5 patients (36%) on 20 mg/day (p = 0.128). Mean CDRS-R scores improved in both treatment groups (fluoxetine 40-60 mg/day, -9.4; fluoxetine 20 mg/day, -1.5; p = 0.099). Adverse events were similar in both groups. However, this study phase was statistically underpowered for detecting differences between treatment groups. Conclusion: More than two thirds of patients whose dosage was increased responded within 10 weeks, suggesting dose escalation may benefit some patients. Approximately one third of patients unresponsive to initial treatment with fluoxetine 20 mg responded to this fixed dosage within another 10 weeks. Fluoxetine 20-60 mg/day was well tolerated.

AB - Objective: The aim of this study was to compare fluoxetine dosage titration to 40-60 mg/day with fixed fluoxetine 20-mg/day treatment for an additional 10 weeks in pediatric outpatients with major depressive disorder (MDD) who had not met protocol-defined response criteria after 9-week acute fluoxetine treatment. Methods: Patients unresponsive (less than or equal to 30% decrease in Children's Depression Rating Scale-Revised [CDRS-R] score) after 9-week fluoxetine treatment were randomly reassigned to continue at 20 mg/day or to increase to 40 mg/day. After 4 weeks, patients unresponsive to 40 mg/day could receive 60 mg/day. Results: Twenty-nine (29) patients, 9-17 years of age, received fluoxetine 40-60 mg/day (n = 14) or 20 mg/day (n = 15). At the conclusion of this study phase, 10 patients (71%) on 40-60 mg/day met the response criteria, versus 5 patients (36%) on 20 mg/day (p = 0.128). Mean CDRS-R scores improved in both treatment groups (fluoxetine 40-60 mg/day, -9.4; fluoxetine 20 mg/day, -1.5; p = 0.099). Adverse events were similar in both groups. However, this study phase was statistically underpowered for detecting differences between treatment groups. Conclusion: More than two thirds of patients whose dosage was increased responded within 10 weeks, suggesting dose escalation may benefit some patients. Approximately one third of patients unresponsive to initial treatment with fluoxetine 20 mg responded to this fixed dosage within another 10 weeks. Fluoxetine 20-60 mg/day was well tolerated.

UR - http://www.scopus.com/inward/record.url?scp=33645818949&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645818949&partnerID=8YFLogxK

U2 - 10.1089/cap.2006.16.207

DO - 10.1089/cap.2006.16.207

M3 - Article

VL - 16

SP - 207

EP - 217

JO - Journal of Child and Adolescent Psychopharmacology

JF - Journal of Child and Adolescent Psychopharmacology

SN - 1044-5463

IS - 1-2

ER -